Literature DB >> 25022632

Evolution of lipid management guidelines: evidence might set you free.

N John Bosomworth1.   

Abstract

OBJECTIVE: To understand how the new guidelines for management of cardiovascular risk by the American Heart Association and the American College of Cardiology (AHA-ACC) can be interpreted and used in a Canadian setting. SOURCES OF INFORMATION: The AHA-ACC guidelines were reviewed, along with all references. Independent PubMed searches were done to include the addition of other lipid-lowering therapy to statins and the use of medical calculators to enhance patient understanding. MAIN MESSAGE: The new AHA-ACC guidelines are based on the best current evidence related to lipid management. This includes use of 10-year cardiovascular disease (CVD) risk as the treatment threshold in place of low-density lipoprotein cholesterol levels, as well as abandonment of low-density lipoprotein treatment targets. There is increased emphasis on dietary and exercise interventions, with the beginning of an effort to quantify the effect of these interventions. Statins are the main drug intervention, and the addition of other drugs to augment lipid lowering is no longer recommended. For application in Canada, Framingham risk tables are more appropriate for risk assessment than the pooled cohort equations used in the United States. Risk calculators for CVD risk should contain information on cardiovascular age and have the ability to represent risk and alternative interventions graphically in order to improve patient understanding and promote informed decision making.
CONCLUSION: Focus on the best evidence in CVD risk can simplify lipid management for both the physician and the patient. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25022632      PMCID: PMC4096258     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  39 in total

1.  Addressing modifiable risk factors for coronary heart disease in primary care: an evidence-base lost in translation.

Authors:  Safia Debar; Pushpa Kumarapeli; Juan Carlos Kaski; Simon de Lusignan
Journal:  Fam Pract       Date:  2010-04-22       Impact factor: 2.267

Review 2.  Statin-induced myopathies.

Authors:  Michał Tomaszewski; Karolina M Stępień; Joanna Tomaszewska; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2011       Impact factor: 3.024

3.  We need minimally disruptive medicine.

Authors:  Carl May; Victor M Montori; Frances S Mair
Journal:  BMJ       Date:  2009-08-11

4.  Clinical inertia as a clinical safeguard.

Authors:  Dario Giugliano; Katherine Esposito
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

Review 5.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

6.  Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study.

Authors:  Chi Pang Wen; Jackson Pui Man Wai; Min Kuang Tsai; Yi Chen Yang; Ting Yuan David Cheng; Meng-Chih Lee; Hui Ting Chan; Chwen Keng Tsao; Shan Pou Tsai; Xifeng Wu
Journal:  Lancet       Date:  2011-08-16       Impact factor: 79.321

Review 7.  Weight science: evaluating the evidence for a paradigm shift.

Authors:  Linda Bacon; Lucy Aphramor
Journal:  Nutr J       Date:  2011-01-24       Impact factor: 3.271

8.  Reductions in incident coronary heart disease risk above guideline physical activity levels in men.

Authors:  Paul T Williams
Journal:  Atherosclerosis       Date:  2009-09-16       Impact factor: 5.162

9.  Physical activity in statin-treated patients.

Authors:  Luca Mascitelli; Francesca Pezzetta
Journal:  Int J Cardiol       Date:  2008-03-26       Impact factor: 4.164

Review 10.  Fat or fit: what is more important?

Authors:  Vojtech Hainer; Hermann Toplak; Vladimír Stich
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.